Statement Of Cash Flows

Oncolys BioPharma Inc. - Filing #7269903

Concept As at
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows
Statement of cash flows
Cash flows from operating activities
Subtotal
-2,014,856,000 JPY
-1,359,074,000 JPY
Interest and dividends received
2,049,000 JPY
616,000 JPY
Interest paid
-4,337,000 JPY
-3,836,000 JPY
Net cash provided by (used in) operating activities
-2,020,088,000 JPY
-1,336,922,000 JPY
Cash flows from operating activities
Cash flows from operating activities
Cash flows from facilities maintenance and investing activities
Purchase of property, plant and equipment
-3,519,000 JPY
-5,686,000 JPY
Proceeds from sale of property, plant and equipment
JPY
136,000 JPY
Cash flows from investing activities
Net cash provided by (used in) investing activities
-4,705,000 JPY
-5,392,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
2,890,817,000 JPY
1,223,450,000 JPY
Proceeds from long-term borrowings
100,000,000 JPY
100,000,000 JPY
Net cash provided by (used in) financing activities
2,879,444,000 JPY
1,142,542,000 JPY
Repayments of long-term borrowings
-94,444,000 JPY
-194,444,000 JPY
Effect of exchange rate change on cash and cash equivalents
23,504,000 JPY
21,334,000 JPY
Net increase (decrease) in cash and cash equivalents
878,155,000 JPY
-178,437,000 JPY
Cash and cash equivalents
2,165,918,000 JPY
1,287,763,000 JPY
1,466,201,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.